FDA Expands Indication for Spinal Muscular Atrophy Drug FDA Expands Indication for Spinal Muscular Atrophy Drug

Originally approved for children with spinal muscular atrophy aged 2 months and older, risdiplam is now indicated for presymptomatic children younger than 2 months.FDA Approvals
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news